Background
==========

Ultrasound (US)-guided vascular cannulation has become more popular in recent years, and US is a proven tool to increase the success rate and decrease complications in a wide variety of vascular catheterization procedures.[@b1-tcrm-14-331] Numerous meta-analyses[@b2-tcrm-14-331]--[@b7-tcrm-14-331] have demonstrated the advantage of US-guided vascular catheterization over a blind landmark approach. However, there is a controversy regarding which approach is preferable for the US probe, ie, the short-axis out-of-plane (SA-OOP) approach or the long-axis in-plane (LA-IP) approach. Each approach has distinct advantages and disadvantages that may either increase or decrease complications.[@b8-tcrm-14-331] In the SA-OOP approach, the relationships of the target vessel to the adjacent vessels are visualized, but the needle tip may not be continuously visualized during catheter placement. In the LA-IP approach, the needle path including the tip can be continuously visualized during catheterization; however, the relationship of the target vessel to adjacent vessels may be lost.[@b9-tcrm-14-331] A previous meta-analysis of five studies showed that there is insufficient evidence to definitively determine which approach is superior in patients undergoing US-guided vascular catheterization.[@b10-tcrm-14-331] Several randomized controlled trials (RCTs) on this topic have been published recently. Therefore, we performed this updated meta-analysis of RCTs to compare the efficacy and safety of these two techniques and further applied trial sequential analysis (TSA) to determine whether the currently available evidence was sufficient and conclusive. This in turn can provide more reliable evidence for clinical practice.

Materials and methods
=====================

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA statement) guidelines were used to perform this meta-analysis.[@b11-tcrm-14-331] Ethical approval was not required.

Search strategy and study selection
-----------------------------------

A search of the PubMed (US National Library of Medicine, Bethesda, MD, USA), Embase, and Cochrane Central Register of Controlled Trials databases was conducted from database inception to August 2017. Specific search strategies were developed for each database using exploded Medical Subject Headings and the appropriate corresponding keywords including "ultrasound," "ultrasonography," "ultrasonic" AND "catheterization," "cannulation," "catheter," "catheters," "insertion" AND "long axis," "short axis," "in plane," "out of plane," "longitudinal," "transverse" AND "RCTs." In addition, the reference lists of the screened full-text studies were searched to identify other potentially eligible trials. Searches were performed without language restrictions. A further search by manually reviewing conference proceedings and the references of review articles was performed.

The inclusion criteria were as follows: 1) population: adult patients requiring vascular catheterization; 2) comparison: the study compared LA-IP vs SA-OOP techniques for US-guided vascular catheterization; 3) outcome measure: the total success rate was reported; and 4) study design: RCTs.

Data extraction and outcome measurement
---------------------------------------

Two investigators (CL and ZM) independently performed the study selection. When data were missing or incomplete, the original authors were contacted by written correspondence for clarification. Disagreements between the two investigators were resolved by consensus or adjudicated by a third investigator (FZ). The dynamic needle tip positioning (DNTP) technique was classified as the SA-OOP approach. One standard form was used for data collection, which included the following information: first author, year of publication, patient population, the number of patients, age of patients, total success rate, first-attempt success rate, cannulation time, number of attempts, experience of the operators, puncture site, and type of US equipment. The primary outcome was the total success rate, and secondary outcomes included the first-attempt success rate, cannulation time, and the number of attempts.

Risk of bias assessment
-----------------------

We assessed the internal validity of included trials using the Cochrane Collaboration Risk of Bias tool.[@b12-tcrm-14-331] The criteria in the tool included a description of the random sequence generation, allocation concealment, blinding of outcome assessment, incomplete outcome data, selective reporting, and other bias. Criteria were individually scored as high, low, or unclear risk of bias.

Statistical analysis
--------------------

The statistical analysis was performed using RevMan software (version 5.3; Cochrane Collaboration, Copenhagen, Denmark) for outcome measurements. The results of the risk ratio (RR) for dichotomous outcomes or the mean difference (MD) for continuous data were expressed as means and 95% CIs. A random-effects model was used regardless of heterogeneity, which was estimated using the *I*^2^ statistic. A value of *I*^2^\>50% indicated significant heterogeneity.[@b13-tcrm-14-331] Potential sources of heterogeneity were identified by sensitivity analyses. We further conducted subgroup analyses according to the puncture site. Publication bias was assessed using the Begg and Egger tests. *P*\<0.05 was considered to indicate a statistically significant difference. The sample mean and SD were estimated according to the sample size, median, range, and/or interquartile range.[@b14-tcrm-14-331]

TSA
---

An updated meta-analysis with new studies may result in false positive results; thus, to decrease the risk of type I errors, the TSA was used. This method can determine whether the present evidence is reliable and conclusive.[@b15-tcrm-14-331] When the cumulative Z-curve crosses the trial sequential monitoring boundary or enters the futility area, a sufficient level of evidence for the anticipated intervention effect may have been reached, and no further trials are needed. If the Z-curve does not cross any of the boundaries and the required information size (RIS) has not been reached, evidence to reach a conclusion is insufficient, and more trials are needed to confirm the results. For this TSA, we estimated the RIS using α=0.05 (two sided), β=0.10 (power 90%), the control event proportions calculated from the long-axis group, and a relative risk reduction of 10% in outcomes. TSA was conducted using TSA Version 0.9 Beta ([www.ctu.dk/tsa](http://www.ctu.dk/tsa)).[@b16-tcrm-14-331]

Results
=======

Study enrolment and characteristics
-----------------------------------

A total of 348 potentially relevant studies were collected, of which 334 studies were excluded based on titles, abstracts, and duplicate studies. Three articles were excluded because the article type was a letter or meta-analysis. Ultimately, 11 studies[@b17-tcrm-14-331]--[@b27-tcrm-14-331] fulfilled the inclusion criteria for the meta-analysis ([Figure 1](#f1-tcrm-14-331){ref-type="fig"}). The study characteristics are summarized in [Table 1](#t1-tcrm-14-331){ref-type="table"}. These studies were published between 2011 and 2017, and a total of 1,210 patients were included. The sample size of the studies ranged from 40 to 190 subjects. Baseline characteristics were similar between the two groups. All of the operators had experience in US-guided vascular catheterization. All studies reported the total success rate, and various complications were reported among these studies. The details for the risk of bias tool are shown in [Figure 2](#f2-tcrm-14-331){ref-type="fig"}. No study fulfilled all criteria for a low risk of bias. A randomized sequence was adequately generated in all studies. Due to the nature of the studies, it was impossible to perform the study blinded. No potential publication bias was observed for primary outcomes (data not shown).

Primary outcome
---------------

### Total success rate

All studies investigated the total success rate of both the SA-OOP and LA-IP approaches for US-guided vascular catheterization. No significant difference was observed between the two groups (RR, 1.01; 95% CI, 0.99--1.04; *P*=0.35; *I*^2^=48%; [Figure 3](#f3-tcrm-14-331){ref-type="fig"}). Subgroup analyses were performed to investigate the source of heterogeneity. In the radial artery (RA) subgroup,[@b19-tcrm-14-331],[@b21-tcrm-14-331],[@b26-tcrm-14-331],[@b27-tcrm-14-331] the total success rate was no different between the SA-OOP and LA-IP groups (RR, 1.00; 95% CI, 0.96--1.05; *P*=0.88; *I*^2^=49%; [Figure 3](#f3-tcrm-14-331){ref-type="fig"}), and the TSA confirmed this result (the cumulative Z-curve crossed the futility boundary and entered the futility area; [Figure 4A](#f4-tcrm-14-331){ref-type="fig"}). In the internal jugular vein (IJV) subgroup,[@b17-tcrm-14-331],[@b20-tcrm-14-331],[@b22-tcrm-14-331],[@b23-tcrm-14-331] the total success rate was also no different between the SA-OOP and LA-IP groups (RR, 1.00; 95% CI, 0.98--1.02; *P*=0.99; *I*^2^=0%; [Figure 3](#f3-tcrm-14-331){ref-type="fig"}) and the TSA also confirmed the result (the cumulative Z-curve crossed the futility boundary and entered the futility area; [Figure 4B](#f4-tcrm-14-331){ref-type="fig"}). Only one study[@b25-tcrm-14-331] was included in the subclavian vein (SCV) subgroup, and the results show that the SA-OOP approach was more efficacious than the LA-IP approach in increasing the total success rate (RR, 1.23; 95% CI, 1.10--1.38; *P*\<0.01; [Figure 3](#f3-tcrm-14-331){ref-type="fig"}).

Secondary outcomes
------------------

### First-attempt success rate

Nine studies[@b17-tcrm-14-331],[@b19-tcrm-14-331],[@b21-tcrm-14-331]--[@b27-tcrm-14-331] reported the first-attempt success rate. There was no significant difference between the LA-IP approach group and the SA-OOP approach group (RR, 1.14; 95% CI, 0.96--1.35, *P*=0.14, *I*^2^=80%; [Figure 5](#f5-tcrm-14-331){ref-type="fig"}). Due to remarkable heterogeneity, preset subgroup analyses were performed for the populations with RA catheterization (RR, 1.03; 95% CI, 0.77--1.38; *P*=0.85, *I*^2^=84%; [Figure 5](#f5-tcrm-14-331){ref-type="fig"}) and IJV catheterization (RR, 1.12; 95% CI, 0.84--1.49; *P*=0.33; *I*^2^=74%; [Figure 5](#f5-tcrm-14-331){ref-type="fig"}). No significant differences were observed. For populations with SCV catheterization[@b25-tcrm-14-331] and axillary vein catheterization,[@b24-tcrm-14-331] the SA-OOP approach showed a benefit.

Other secondary outcomes are summarized in [Table 2](#t2-tcrm-14-331){ref-type="table"}, including cannulation times, the number of attempts, complications of hematoma, and arterial puncture. The cannulation times of the two approaches used in the US-guided RA and IJV catheterization were similar. The number of attempts may be reduced when the SA-OOP approach is used in US-guided IJV catheterization and the LA-IP approach is used in US-guided RA catheterization. No significant differences were observed when comparing the complications of hematoma and arterial puncture between the two approaches.

Discussion
==========

The key findings of this updated meta-analysis are as follows. 1) The total success rate was similar between the SA-OOP approach and LA-IP approach when used for RA and IJV catheterization, as confirmed by TSA. The SA-OOP approach showed a benefit when used for SCV catheterization; however, further RCTs are needed to confirm this. 2) The first-attempt success rate was also similar between the two approaches when used for US-guided RA or IJV catheterization. Whether the SA-OOP approach has an advantage in increasing the first-attempt success rate when used for SCV and axillary vein catheterization also requires further studies to confirm or refute this finding. 3) The number of attempts may be reduced when the SA-OOP approach is used in US-guided IJV catheterization and when the LA-IP approach is used in US-guided RA catheterization. 4) No significant differences in cannulation times or complications were found between the two approaches.

There are several differences between our meta-analysis and a previous meta-analysis.[@b10-tcrm-14-331] First, this meta-analysis included an additional six studies.[@b22-tcrm-14-331]--[@b27-tcrm-14-331] Thus, this updated meta-analysis represents the latest and most comprehensive study. Second, TSA was further applied to better establish sufficient and conclusive evidence. Third, we also analyzed the difference between the two approaches when used in different vessels.

In this meta-analysis, the total success rate was similar when the two approaches were used for US-guided RA and IJV catheterization and was confirmed by TSA. Moreover, more studies are needed to further evaluate whether the complications, first-attempt success rate, and cannulation times are different between the two approaches. A study[@b25-tcrm-14-331] included in this meta-analysis showed that the SA-OOP approach may increase the total success rate when used for SCV catheterization; however, this led to controversy.[@b28-tcrm-14-331] High-quality studies are needed to confirm or refute this finding.

One study[@b26-tcrm-14-331] included in this meta-analysis reported that the oblique approach for US-guided RA catheterization may replace the two classic approaches due to its superior success rate, higher first-attempt success, and shorter time consumed for catheterization with higher operator satisfaction after the procedure. Confirmation of this requires further research. Another study[@b22-tcrm-14-331] in this meta-analysis compared three transducer orientation approaches for US-guided IJV catheterization and found that the oblique-axis (OAX) approach showed a higher first-needle pass success rate than LA-IP approach and a lower mechanical complications rate than the SA-OOP approach. Although more clinical studies are needed, this new approach may be superior in reducing complications related to IJV catheterization.

US-guidance for vascular catheterization is a user-dependent technology, and it is necessary to use medical simulators to train novice US users before they practice on patients. However, there are some discrepancies between the medical simulator result and the patient result. For example, one study[@b29-tcrm-14-331] evaluated the two approaches used in SCV catheterization in a human torso mannequin and found that the LA-IP view for SCV catheterization was more efficient with a decreased time to cannulation and fewer redirections. The simulators could not reflect the actual circumstances of the patients, and they lacked the nerves and arteries from soft tissue that commonly complicate US-guided vascular catheterization.[@b30-tcrm-14-331] Hence, whether the benefit obtained from the medical simulators can be proven in live patients is unknown. Therefore, to provide more reliable evidence for clinical practice, more high-quality, anatomically accurate, vascular phantoms and standardized performance procedures are needed for US training.[@b31-tcrm-14-331] Furthermore, when using the medical simulator to train novice US users, we should carefully consider the discrepancy between the medical simulator and the patient to improve clinical practice.

This meta-analysis has several potential limitations. First, considerable heterogeneity was observed between the included studies with respect to blood vessel type, operator experience, US equipment, and outcome definition, which could have influenced the results; second, due to the limited data, it is difficult to perform more subgroup or sensitivity analyses. Third, double blinding was not performed due to the features of the trials, which may result in performance and detection bias.

Conclusion
==========

A similar total success rate between the SA-OOP approach and the LA-IP approach for RA and IJV catheterization was confirmed by TSA. However, further robust and well-designed trials are warranted to evaluate other outcomes. There is insufficient evidence to definitively state that the SA-OOP approach was better than the LA-IP approach when used for SCV and axillary vein catheterization. High-quality trials are needed to confirm or refute this finding.
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![Forest plot of total success rate.\
**Abbreviation:** M--H, Mantel--Haenszel.](tcrm-14-331Fig3){#f3-tcrm-14-331}

![TSA result.\
**Notes:** (**A**) RA subgroup. The DL approach of TSA used for the total success rate. A diversity-adjusted information size of 595 participants was calculated on the basis of a total success rate of 92.5% in the long-axis group with a relative risk reduction of 10%, α=5% (two sided), β=10% (power 90%), and *I*^2^=0%. The solid blue line represents a cumulative Z-curve, which crossed the futility boundary (complete red line) and reached the futility area. (**B**) IJV subgroup. The DL approach of TSA was used for the total success rate. A diversity-adjusted information size of 240 participants was calculated on the basis of a total success rate of 99% in the long-axis group with a relative risk reduction of 10%, α=5% (two sided), β=10% (power 90%), and *I*^2^=0%. The complete blue line represents the cumulative Z-curve, which entered the futility area and crossed the required information size boundary.\
**Abbreviations:** DL, DerSimonian--Laird; IJV, internal jugular vein; M--H, Mantel--Haenszel; RA, radial artery; TSA, trial sequential analysis.](tcrm-14-331Fig4){#f4-tcrm-14-331}
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###### 

Characteristics of the 11 included trials

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                                  Site                     No of patients (M/F)   Patient population                                                         Mean age (years)                                           Weight                 Total success rate (%)   First attempt success rate (%)   Cannulation time                                            No of attempts                                             No of needle redirections                                  Hematoma   Arterial puncture   Operator                                                                                                                                                              Ultrasound equipment
  ------------------------------------------------------ ------------------------ ---------------------- -------------------------------------------------------------------------- ---------------------------------------------------------- ---------------------- ------------------------ -------------------------------- ----------------------------------------------------------- ---------------------------------------------------------- ---------------------------------------------------------- ---------- ------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Sethi et al (2017; India)[@b27-tcrm-14-331]            RA                       S: 75 (46/29)\         Surgical patients indicated for arterial catheterization                   S: 59.5±8.2[a](#tfn1-tcrm-14-331){ref-type="table-fn"}\    S: 62.8±11.6 (kg)\     S: 92.0\                 S: 80.0\                         S: 28.4±8.2[a](#tfn1-tcrm-14-331){ref-type="table-fn"}\     NR                                                         NR                                                         S: 8\      NR                  Anesthetists had placed more than 100 arterial lines by using either in-plane or out-of-plane approaches                                                              Probe (MicroMaxx^®^ SLA/13-6 MHz, SonoSite Inc., Bothell, WA, USA), ultrasound system (SonoSite^®^ MicroMaxx^®^ Ultrasound System, SonoSite Inc.)
                                                                                  L: 75 (41/34)                                                                                     L: 57.7±7.6[a](#tfn1-tcrm-14-331){ref-type="table-fn"}     L: 64.6±12.2 (kg)      L: 93.3                  L: 82.7                          L: 27.6±7.6[a](#tfn1-tcrm-14-331){ref-type="table-fn"}                                                                                                                            L: 0                                                                                                                                                                                                 

  Abdalla et al (2017; Egypt)[@b26-tcrm-14-331]          RA                       S: 42 (NR)\            Surgical and ICU patients indicated for arterial catheterization           S: 55±11[a](#tfn1-tcrm-14-331){ref-type="table-fn"}\       S: 84±32 (kg)\         S: 60\                   S: 50\                                                                                                                                                                                                                                                                                                                                                                                                                  
                                                                                  L: 42 (NR)                                                                                        L: 59±9[a](#tfn1-tcrm-14-331){ref-type="table-fn"}         L: 84±31 (kg)          L: 70                    L: 27                                                                                                                                                                                                                                                                                                                                                                                                                   

  Vezzani et al (2017; Italy)[@b25-tcrm-14-331]          SCV                      S: 95 (74/21)\         Patients undergoing cardiac surgery                                        S: 70±13[a](#tfn1-tcrm-14-331){ref-type="table-fn"}\       S: 26±4 (BMI)\         S: 96\                   S: 86\                           S: 28±19[a](#tfn1-tcrm-14-331){ref-type="table-fn"}\        S: 1.6±0.8[a](#tfn1-tcrm-14-331){ref-type="table-fn"}\     NR\                                                        S: 11\     NR\                 Expert operators Anesthesiologists with 3- and 6-year experience in US-guided central vein cannulation                                                                Toshiba Xario, Japan, PLT-805AT transducer Philips CX50 system (Philips Healthcare, Eindhoven, the Netherlands) equipped with a high-frequency, linear array probe at 10 MHz
                                                                                  L: 95 (68/27)                                                                                     L: 71±12[a](#tfn1-tcrm-14-331){ref-type="table-fn"}        L: 27±5 (BMI)          L: 78                    L: 67                            L: 66±5[a](#tfn1-tcrm-14-331){ref-type="table-fn"}\         L: 1.8±0.7[a](#tfn1-tcrm-14-331){ref-type="table-fn"}NR    S: 0.39±0.88[a](#tfn1-tcrm-14-331){ref-type="table-fn"}\   L: 11\     S: 0\                                                                                                                                                                                     
                                                                                                                                                                                                                                                                                                                                S: 69±74[a](#tfn1-tcrm-14-331){ref-type="table-fn"}\                                                                   L: 0.88±1.15[a](#tfn1-tcrm-14-331){ref-type="table-fn"}    S: 0\      L: 7                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                L: 98±103[a](#tfn1-tcrm-14-331){ref-type="table-fn"}                                                                                                                              L: 1                                                                                                                                                                                                 

  Maddali et al (2017; Oman)[@b24-tcrm-14-331]           Axillary vein            S: 43 (NR)\            Adult cardiac surgical patients                                            S: 59.7±13.0[a](#tfn1-tcrm-14-331){ref-type="table-fn"}\   S: 27.4±5.1 (BMI)\     S: 97.7\                 S: 79.1\                         S: 414±228[a](#tfn1-tcrm-14-331){ref-type="table-fn"}\      S: 1.4±0.7[a](#tfn1-tcrm-14-331){ref-type="table-fn"}\     S: 1.3±0.9[a](#tfn1-tcrm-14-331){ref-type="table-fn"}\     S: 1\      S: 1\               Experienced anesthetists                                                                                                                                              12L-RS linear array transducer from GE (frequency range, 5--15 MHz; field of view, 192 mm) compatible with a Logiq E ultrasound machine (GE Healthcare, Wauwatosa, WI, USA)
                                                                                  L: 43 (NR)                                                                                        L: 61.8±13.8[a](#tfn1-tcrm-14-331){ref-type="table-fn"}    L: 26.0±4.3 (BMI)      L: 90.7                  L: 46.5                          L: 618±312[a](#tfn1-tcrm-14-331){ref-type="table-fn"}       L: 1.8±0.9[a](#tfn1-tcrm-14-331){ref-type="table-fn"}      L: 1.0±1.15[a](#tfn1-tcrm-14-331){ref-type="table-fn"}     L: 2       L: 4                                                                                                                                                                                      

  Shrestha et al (2016; Nepal)[@b23-tcrm-14-331]         IJV                      S: 41 (23/18)\         Adult subjects presenting for elective surgery or in intensive care unit   S: 59.7±22.0[a](#tfn1-tcrm-14-331){ref-type="table-fn"}\   NR                     S: 100\                  S: 51.2\                         NR                                                          NR                                                         NR                                                         NR         S: 1\               Experienced anesthetists with a minimum of 3 years of experience in cannulation of central veins                                                                      A 6-10 L38 MHz linear transducer SonoSite Turbo unit (SonoSite, MicroMaxx, Bothwell, WA, USA)
                                                                                  L: 41 (30/11)                                                                                     L: 49.6±18.6[a](#tfn1-tcrm-14-331){ref-type="table-fn"}                           L: 100                   L: 67.9                                                                                                                                                                                                                       L: 1                                                                                                                                                                                      

  Batllori et al (2016; Spain)[@b22-tcrm-14-331]         IJV                      S: 73 (45/28)\         Patients (aged 18 years or above) in whom IJVC had been indicated          S: 64.9\                                                   S: 27.7±4.8 (BMI)\     S: 97.3\                 S: 69.9\                         S: 35.0±23.4[a](#tfn1-tcrm-14-331){ref-type="table-fn"}\    S: 1.51±0.97[a](#tfn1-tcrm-14-331){ref-type="table-fn"}\   NR                                                         S: 1\      NR                  Anesthetists with appropriate proficiency in ultrasound- guided central venous access                                                                                 S-Nerve ultrasound machine (SonoSite Inc.) with a 13-6 MHz 38-mm linear array probe was used
                                                                                  L: 75 (49/26)                                                                                     L: 64.0                                                    L: 27.3±4.1 (BMI)      L: 97.3                  L: 52                            L: 46.1±36.3[a](#tfn1-tcrm-14-331){ref-type="table-fn"}     L: 1.92±1.36[a](#tfn1-tcrm-14-331){ref-type="table-fn"}                                                               L: 2                                                                                                                                                                                                 

  Quan et al (2014; China)[@b21-tcrm-14-331]             RA                       S: 81 (59/22)\         Undergo liver surgery or splenic resection under general anesthesia        S: 49.2±8.1[a](#tfn1-tcrm-14-331){ref-type="table-fn"}\    S: 76.4±12.2 (kg)\     S: 100\                  S: 88.9\                         S: 29.7±17.2[a](#tfn1-tcrm-14-331){ref-type="table-fn"}\    NR                                                         NR                                                         S: 12\     NR                  Experienced anesthetists, who had previously cannulated 450 radial arteries and used the ultrasound-guided technique for approximately 200 procedures                 Terason2000^+^; Terason, Burlington, MA, USA
                                                                                  L: 82 (64/18)                                                                                     L: 46.1±7.9[a](#tfn1-tcrm-14-331){ref-type="table-fn"}     L: 72.1±10.5 (kg)      L: 97.6                  L: 73.2                          L: 26.2±9.8[a](#tfn1-tcrm-14-331){ref-type="table-fn"}                                                                                                                            L: 15                                                                                                                                                                                                

  Tammam et al (2013; Egypt)[@b20-tcrm-14-331]           IJV                      S: 30 (13/17)\         Critical care and hemodialysis patients                                    S: 56.0±14.5[a](#tfn1-tcrm-14-331){ref-type="table-fn"}\   S: 27.41±7.17 (BMI)\   S: 100\                  NR                               S: 52.3±11.91[a](#tfn1-tcrm-14-331){ref-type="table-fn"}\   S: 1.13±0.35[a](#tfn1-tcrm-14-331){ref-type="table-fn"}\   NR                                                         S: 1\      S: 1\               Well-trained attending anesthetists, nephrologists, or intensivists with similar experience (at least 5 years of experience in performing ultrasound-guided method)   Portable unit (GE LogiqBook XP Portable Ultrasound Machine; General Electric Company, GE Healthcare -- Americas, USA) and a 10 MHz linear-array US probe
                                                                                  L: 30 (16/14)                                                                                     L: 51.3±15.3[a](#tfn1-tcrm-14-331){ref-type="table-fn"}    L: 28.15±8.20 (BMI)    L: 100                                                    L: 52.7±11.74[a](#tfn1-tcrm-14-331){ref-type="table-fn"}    L: 1.17±0.38[a](#tfn1-tcrm-14-331){ref-type="table-fn"}                                                               L: 0       L: 0                                                                                                                                                                                      

  Berk et al (2013; Turkey)[@b19-tcrm-14-331]            RA                       S: 54 (23/31)\         ASA I--III, require an arterial catheter                                   S: 56±1[a](#tfn1-tcrm-14-331){ref-type="table-fn"}\        S: 78±18 (kg)\         S: 100\                  S: 51\                           S: 46.8±34[a](#tfn1-tcrm-14-331){ref-type="table-fn"}\      S: 1.5±0.5[a](#tfn1-tcrm-14-331){ref-type="table-fn"}\     S: 2±1[a](#tfn1-tcrm-14-331){ref-type="table-fn"}\         S: 23\     NR                  Anesthetists (had placed more than 50 ultrasound- guided arterial lines)                                                                                              Ultrasound system (Esaote My Lab 30, US Machine, Florence, Italy) and a linear probe with 18 MHz frequency
                                                                                  L: 54 (30/24)                                                                                     L: 54±2[a](#tfn1-tcrm-14-331){ref-type="table-fn"}         L: 76±16 (kg)          L: 100                   L: 76                            L: 23.7±17[a](#tfn1-tcrm-14-331){ref-type="table-fn"}       L: 1.27±0.4[a](#tfn1-tcrm-14-331){ref-type="table-fn"}     L: 1.5±0.6[a](#tfn1-tcrm-14-331){ref-type="table-fn"}      L: 2                                                                                                                                                                                                 

  Mahler et al (2011; United States)[@b18-tcrm-14-331]   Peripheral intravenous   S: 20 (6/14)\          Difficult IV access patients in the ED                                     S: 48±15[a](#tfn1-tcrm-14-331){ref-type="table-fn"}\       C: 201±54 (Ib)\        S: 95\                   NR                               S: 34 (35)^c^\                                              S: 1.5±0.7[a](#tfn1-tcrm-14-331){ref-type="table-fn"}\     NR                                                         NR         NR                  ED attending physicians and nurses (more than 20 ultrasound-guided peripheral or central lines)                                                                       Single-operator technique and 5--10 MHz, L38 probe on a SonoSite MicroMaxx; SonoSite Inc.
                                                                                  L: 20 (9/11)                                                                                      L: 47±14[a](#tfn1-tcrm-14-331){ref-type="table-fn"}        H: 202±66 (Ib)         L: 85                                                     L: 96 (59)^c^                                               L: 1.4±0.7[a](#tfn1-tcrm-14-331){ref-type="table-fn"}                                                                                                                                                                                                                                                                      

  Chittoodan et al (2011; Ireland)[@b17-tcrm-14-331]     IJV                      S: 49 (37/12)\         Adult subjects presenting for elective cardiac surgery                     S: 62.9±13.2[a](#tfn1-tcrm-14-331){ref-type="table-fn"}\   S: 85.2±13.5 (kg)\     S: 100\                  S: 98\                           S: 39.6±18.4[a](#tfn1-tcrm-14-331){ref-type="table-fn"}\    S: 1.02±0.2[a](#tfn1-tcrm-14-331){ref-type="table-fn"}\    NR                                                         NR         S: 0\               Anesthetists (more than 50 ultrasound-guided internal jugular cannulations)                                                                                           A 6--10 L38 MHz linear transducer SonoSite Titanunit (SonoSite, MicroMaxx; SonoSite Inc.)
                                                                                  L: 50 (37/13)                                                                                     L: 62.9±13.1[a](#tfn1-tcrm-14-331){ref-type="table-fn"}    L: 84.1±15.7 (kg)      L: 100                   L: 78                            L: 46.9±42.4[a](#tfn1-tcrm-14-331){ref-type="table-fn"}     L: 1.24±0.56[a](#tfn1-tcrm-14-331){ref-type="table-fn"}                                                                          L: 2                                                                                                                                                                                      
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Note:**

Mean ± SD.

**Abbreviations:** ASA, American Society of Anesthesiologists; BMI, body mass index; ED, emergency department; IJV, internal jugular vein; IJVC, internal jugular vein cannulation; L, long axis; NR, not reported; RA, radial artery; RCT, randomized controlled trials; S, short axis; SCV, subclavian vein.

###### 

Secondary outcomes

                                                                                                                             No of studies                                                                                                                                  No of patients       MD (95% CI)               Heterogeneity *I*^2^ (*P*-value)       Test for effect (*P*-value)       
  -------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------- -------------------- ------------------------- -------------------------------------- --------------------------------- ------
  Cannulation time                                                                                                           3[@b17-tcrm-14-331],[@b20-tcrm-14-331],[@b22-tcrm-14-331],[a](#tfn3-tcrm-14-331){ref-type="table-fn"}                                          152                  155                       −5.15 (−12.28 to 1.97)                 45% (\<0.01)                      0.16
  4[@b19-tcrm-14-331],[@b21-tcrm-14-331],[@b26-tcrm-14-331],[@b27-tcrm-14-331],[a](#tfn4-tcrm-14-331){ref-type="table-fn"}   252                                                                                                                                            253                  −2.93 (−21.10 to 15.25)   98% (\<0.01)                           0.75                              
  Number of attempts                                                                                                         5[@b17-tcrm-14-331]--[@b20-tcrm-14-331],[@b22-tcrm-14-331],[@b24-tcrm-14-331],[@b26-tcrm-14-331],[c](#tfn5-tcrm-14-331){ref-type="table-fn"}   311                  314                       −0.12 (−0.30 to 0.07)                  74% (\<0.01)                      0.22
  3[@b17-tcrm-14-331],[@b20-tcrm-14-331],[@b22-tcrm-14-331],[a](#tfn3-tcrm-14-331){ref-type="table-fn"}                      152                                                                                                                                            155                  −0.18 (−0.35 to 0.00)     47% (0.15)                             0.04                              
  1[@b19-tcrm-14-331],[b](#tfn4-tcrm-14-331){ref-type="table-fn"}                                                            54                                                                                                                                             54                   0.23 (0.06 to 0.40)       Not applicable                         \<0.01                            
                                                                                                                                                                                                                                                                                                                                                                                                    
                                                                                                                             **No of studies**                                                                                                                              **No of patients**   **RR (95% CI)**           **Heterogeneity *I*^2^ (*P*-value)**   **Test for effect (*P*-value)**   
  **SA**                                                                                                                     **LA**                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                    
  Hematoma                                                                                                                   6[@b19-tcrm-14-331]--[@b22-tcrm-14-331],[@b26-tcrm-14-331],[@b27-tcrm-14-331],[c](#tfn5-tcrm-14-331){ref-type="table-fn"}                      355                  358                       2.02 (0.68 to 5.98)                    73% (\<0.01)                      0.20
  2[@b19-tcrm-14-331],[@b21-tcrm-14-331],[a](#tfn3-tcrm-14-331){ref-type="table-fn"}                                         103                                                                                                                                            105                  0.97 (0.15 to 6.50)       0% (0.38)                              0.98                              
  4[@b20-tcrm-14-331],[@b22-tcrm-14-331],[@b26-tcrm-14-331],[@b27-tcrm-14-331],[b](#tfn4-tcrm-14-331){ref-type="table-fn"}   252                                                                                                                                            253                  2.49 (0.66 to 9.37)       83% (\<0.01)                           0.18                              
  Arterial puncture                                                                                                          5[@b17-tcrm-14-331],[@b20-tcrm-14-331],[@b23-tcrm-14-331]--[@b25-tcrm-14-331],[c](#tfn5-tcrm-14-331){ref-type="table-fn"}                      258                  259                       0.36 (0.11 to 1.21)                    0% (0.41)                         0.10
  3[@b17-tcrm-14-331],[@b20-tcrm-14-331],[@b23-tcrm-14-331],[a](#tfn3-tcrm-14-331){ref-type="table-fn"}                      120                                                                                                                                            121                  0.83 (0.15 to 4.55)       0% (0.47)                              0.83                              

**Notes:**

Internal jugular vein subgroup.

Radial artery subgroup.

All studies.

**Abbreviations:** LA, long axis; MD, mean difference; RR, relative risk; SA, short axis.

[^1]: These authors contributed equally to this work
